Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients

Study Identifier
192371-014
CT.gov Identifier
NCT00611403
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dry Eye
    • Study Drug
  • Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)
  • Artificial Tears REFRESH ENDURA®
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    21 - 50 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patient is scheduled for bilateral LASIK surgery * Patient is in good general health * Eye glasses prescription of -1 to -8
    Exclusion Criteria:
    * Significant Dry Eye * Presence of eye disease * Uncontrolled systemic disease

    Protocol Summary

    This study will evaluate the safety and efficacy of cyclosporine ophthalmic emulsion administered twice daily following LASIK surgery

    Study Locations

    Location
    Status
    Location
    Overland Park, Kansas, United States
    Status
    Not applicable